



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

## Genomic Diagnosis of Rare Pediatric Disease in the United Kingdom and Ireland

### Citation for published version:

Wright, CF, Campbell, P, Eberhardt, RY, Aitken, S, Perrett, D, Brent, S, Danecek, P, Gardner, EJ, Chundru, VK, Lindsay, SJ, Andrews, KA, Hampstead, J, Kaplanis, J, Samocho, KE, Middleton, A, Foreman, J, Hobson, RJ, Parker, M, Martin, HC, FitzPatrick, DR, Hurles, ME & Firth, HV 2023, 'Genomic Diagnosis of Rare Pediatric Disease in the United Kingdom and Ireland', *New England Journal of Medicine*.  
[https://doi.org/https://www.nejm.org/doi/10.1056/NEJMoa2209046?url\\_ver=Z39.88-2003&rfr\\_id=ori:rid:crossref.org&rfr\\_dat=cr\\_pub%20%20pubmed](https://doi.org/https://www.nejm.org/doi/10.1056/NEJMoa2209046?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed)

### Digital Object Identifier (DOI):

[https://www.nejm.org/doi/10.1056/NEJMoa2209046?url\\_ver=Z39.88-2003&rfr\\_id=ori:rid:crossref.org&rfr\\_dat=cr\\_pub%20%20pubmed](https://www.nejm.org/doi/10.1056/NEJMoa2209046?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed)

### Link:

[Link to publication record in Edinburgh Research Explorer](#)

### Document Version:

Peer reviewed version

### Published In:

New England Journal of Medicine

### Publisher Rights Statement:

Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

### General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

### Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



Copyright © 2023 Author(s), Massachusetts Medical Society. All rights reserved.

This is an Author Accepted Manuscript, which is the version after external peer review and before publication in the Journal. The publisher's version of record, which includes all New England Journal of Medicine editing and enhancements, is available at <https://www.nejm.org/doi/full/10.1056/NEJMoa2209046>.

This Author Accepted Manuscript is licensed for use under the CC-BY license.

## **Genomic Diagnosis of Rare Pediatric Disease in the United Kingdom and Ireland**

Caroline F. Wright Ph.D.<sup>1</sup>, Patrick Campbell M.B.B.S.<sup>2,3</sup>, Ruth Y. Eberhardt Ph.D.<sup>2</sup>, Stuart Aitken Ph.D.<sup>4</sup>, Daniel Perrett M.Phil.<sup>2,5</sup>, Simon Brent B.S.c.<sup>2,5</sup>, Petr Danecek Ph.D.<sup>2</sup>, Eugene J. Gardner Ph.D.<sup>2</sup>, V. Kartik Chundru Ph.D.<sup>2</sup>, Sarah J. Lindsay Ph.D.<sup>2</sup>, Katrina Andrews MB.BC.h.<sup>2</sup>, Juliet Hampstead B.S.c.<sup>2</sup>, Joanna Kaplanis Ph.D.<sup>2</sup>, Kaitlin E. Samocha Ph.D.<sup>2</sup>, Anna Middleton Ph.D.<sup>6</sup>, Julia Foreman Ph.D.<sup>2,5</sup>, Rachel J. Hobson Ph.D.<sup>2</sup>, Michael J. Parker Ph.D.<sup>7</sup>, Hilary C. Martin Ph.D.<sup>2</sup>, David R. FitzPatrick M.D.<sup>4</sup>, Matthew E. Hurles Ph.D.<sup>2</sup> and Helen V. Firth D.M.<sup>2,3</sup> *on behalf of the DDD Study*

### **AFFILIATIONS**

1 Department of Clinical and Biomedical Sciences, University of Exeter Medical School, RILD Building, Royal Devon & Exeter Hospital, Barrack Road, Exeter UK, EX2 5DW

2 Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge UK, CB10 1SA

3 Cambridge University Hospitals Foundation Trust, Addenbrooke's Hospital, Cambridge UK, CB2 0QQ

4 MRC Human Genetics Unit, Institute of Genetic and Cancer, University of Edinburgh, Edinburgh UK, EH4 2XU

5 European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge UK, CB10 1SD

6 Wellcome Connecting Science, Wellcome Genome Campus, Hinxton, Cambridge, UK,  
CB10 1SA

7 Wellcome Centre for Ethics and Humanities/Ethox Centre, Oxford Population Health,  
University of Oxford, Big Data Institute, Old Road Campus, Oxford, UK, OX3 7LF

**CORRESPONDENCE**

Caroline F. Wright, Ph.D.

[caroline.wright@exeter.ac.uk](mailto:caroline.wright@exeter.ac.uk)

## ABSTRACT

**Background:** Pediatric disorders include a range of highly genetically heterogeneous conditions amenable to genome-wide diagnostic approaches. Finding a molecular diagnosis is challenging but can have profound lifelong benefits.

**Methods:** The Deciphering Developmental Disorders (DDD) study recruited >13,500 families with severe, likely monogenic, difficult-to-diagnose developmental disorders from 24 regional genetics services around the UK and Ireland. We collected standardised phenotype data and performed exome sequencing and microarray analysis to investigate novel genetic causes. We developed an iterative variant analysis pipeline, reporting candidate variants to clinical teams for validation, diagnostic interpretation and communication to families. We performed multiple regression analyses evaluating factors affecting probability of diagnosis.

**Results:** We reported ~1 candidate variant per parent-offspring trio and ~2.5 variants per singleton proband. Using clinical and computational approaches to variant classification, we achieved a diagnosis in ~41% (5502 probands), of whom ~76% have a pathogenic *de novo* variant. Another 22% have variants of uncertain significance in genes robustly linked with monogenic developmental disorders. Recruitment as a parent-offspring trio had the largest impact on chance of diagnosis (OR=4.70). Probands who were extremely premature (OR=0.39), had *in-utero* exposure to antiepileptic medications (OR=0.44), or whose mothers had diabetes (OR=0.52) were less likely to be diagnosed, as were those of African ancestry (OR=0.51).

**Conclusions:** The DDD study shows multimodal analysis of genome-wide data has good diagnostic power, even after prior attempts at diagnosis.

(Funded by Wellcome Trust and others.)

## INTRODUCTION

Genomic sequencing has made extraordinary strides towards identifying novel molecular causes for rare monogenic disorders, and is becoming increasingly available in diagnostic clinics throughout the world.<sup>1,2</sup> Pediatrics has particularly benefited from the use of high-throughput next generation sequencing technologies, partly because of the high clinical need and potential for lifelong impact of diagnosis and treatment.<sup>3</sup> In addition, the early presentation of severe disease makes genetic diagnosis more tractable as causal variants are largely absent from control datasets.<sup>4</sup>

Progress in pediatric rare disease genomics has been spearheaded by numerous diagnostic research groups across the world.<sup>5,6</sup> One of the first studies to combine large-scale genomic research with individual patient feedback was the Deciphering Developmental Disorders (DDD) study,<sup>7-9</sup> with >13,500 families with exome sequence and microarray data and rich clinical phenotypes recorded by >200 clinicians across the UK and Ireland. Here we describe analytical strategies developed over a decade by the DDD study to identify and classify thousands of new molecular diagnoses, and report factors affecting the probability of receiving a diagnosis.

## METHODS

### STUDY OVERVIEW

The DDD study was granted UK Research Ethics Committee (REC) approval by the Cambridge South REC (10/H0305/83) and Republic of Ireland REC (GEN/284/12). A multicentre research collaboration was set up with all 24 Regional Genetics Services, and a management committee (comprising clinicians, scientists and a bioethicist) was created to provide ongoing ethical oversight (**Table 1**). In addition to genomic and data scientists, a social scientist was employed to do ethics research.<sup>10</sup>

## COHORT

13,610 cases (88% as parent-offspring trios) were ascertained and recruited between April 2011-2015 by consultant clinical geneticists, facilitated by research nurses/genetic counsellors. Families gave informed consent for participation. Eligibility criteria included any of the following: neurodevelopmental disorders; congenital anomalies; abnormal growth parameters (single parameter >4SD or two or more parameters >3SD above the mean); dysmorphic features; unusual behavioural phenotypes; and genetic disorders with a significant impact for which the molecular basis was unknown. The study was initially limited to probands <16 years at the date of recruitment, but this age limit was later removed (except in Scotland). Most probands had previously undergone clinical chromosomal microarray (85%) and/or single gene testing (53%) but remained undiagnosed. Probands were assigned pseudonymised IDs and basic clinical information, quantitative growth data, developmental milestones and Human Phenotype Ontology (HPO)<sup>11</sup> terms were recorded for all participants via a bespoke standardised interface in DECIPHER.<sup>12</sup>

## GENOMIC ANALYSES

Detailed assay protocols<sup>13,14</sup> and variant filtering pipelines<sup>7,15</sup> have been described elsewhere (**Supplementary Information**). Briefly, three independent genomic assays were performed: exome sequencing (ES) of complete family trios and singleton probands (i.e. non-trios); exon-array comparative genomic hybridisation (aCGH) of probands; and genome-wide SNP-genotyping of probands. Assay designs remained largely unchanged throughout the study. Datasets were processed in batches, and multiple different algorithms were used to detect and annotate sequence and structural variants (**Figure 1**). The inheritance status of variants in the proband were determined by comparison with parental data<sup>16</sup>. For clinical reporting, we selected high-quality, rare, non-synonymous variants overlapping genes in the Developmental Disorders Gene2Phenotype database (DDG2P)<sup>17</sup> with appropriate zygosity and inheritance (where available). We augmented this pipeline with additional analyses to

find missing likely causal variants, including ClinVar pathogenic/likely pathogenic variants,<sup>18</sup> and *de novo* variants that were mosaic,<sup>19</sup> created upstream open reading frames,<sup>20</sup> affected splicing,<sup>21</sup> or were coding insertions/deletions of intermediate size<sup>22</sup> or caused by mobile element insertions<sup>23</sup> or mosaic chromosomal alterations.<sup>24</sup>

## DEFINING A DIAGNOSIS

Candidate diagnostic variants identified bioinformatically were reviewed by a central clinical review panel to evaluate analytical and clinical validity prior to reporting in batches to regional genetics teams via DECIPHER (April 2014-2022, **Figure 2**). The referring clinician then evaluated the reported variant(s), requested diagnostic laboratory confirmation where required, and communicated diagnoses to the family. At the time of writing, clinical classifications of variant pathogenicity (benign/ likely benign/ uncertain/ likely pathogenic/ pathogenic) and contribution to the phenotype (full/ partial/ unknown/ none) were recorded in DECIPHER for 84% of variants. These were supplemented by automated predictions for variant classification criteria (BA1, BS1, BP4, BP7, PVS1, PS1, PS2, PP3 and PM2) based on published guidelines from the American College of Medical Genetics and Genomics (ACMG) and Association of Molecular Pathologists<sup>25</sup> and UK Association of Clinical Genetic Scientists (ACGS)<sup>26</sup>. A provisional variant classification was calculated using a log-additive Bayesian framework described elsewhere<sup>27</sup> (**Supplementary Information**). Variants with a posterior probability of >0.9 were classified as likely pathogenic and pathogenic >0.99, or <0.1 as likely benign and benign <0.001. For genes with  $\geq 10$  pathogenic/likely pathogenic variants, computational phenotype matching was performed using IMPROVE-DD,<sup>28</sup> applying the same Bayesian framework to combine variant classifications and gene-disease models; phenotype-based likelihoods were scaled appropriately and used at the evidence equivalent of “Strong”.<sup>27</sup> Proband's were categorised as “diagnosed” if  $\geq 1$  variant(s) or  $\geq 2$  compound heterozygous variants were annotated as pathogenic/likely pathogenic by either the proband's referring clinician and/or the predicted classification, and the contribution to phenotype was not clinically annotated as “none”. Factors influencing the chance of

receiving a diagnosis (based on clinical annotation only) were investigated using multivariable logistic regression with Bonferroni correction to account for multiple hypothesis testing (**Supplementary Information**).

#### DATA AVAILABILITY

A **Supplementary Table** of diagnoses per gene is provided. Individual-level datasets are available under managed access for research into developmental disorders via the European Genome-phenome Archive (EGAS00001000775). Individual pathogenic/likely pathogenic variants are openly accessible with phenotypes via DECIPHER, and are provided in a Supplementary File in the European Genome-Phenome Archive.

## RESULTS

#### COHORT CHARACTERISTICS

The DDD study includes 13,449 probands (9,859 in parent-offspring trios) with severe, previously undiagnosed developmental disorders with ES, exon-aCGH and SNP genotyping data, recruited across the UK and Ireland with a median recruitment per centre of 216 probands per million population (range=69-588). The median age was 7 years (range=0-63) at recruitment for probands and 31 years (range=15-70 at the proband's birth) for parents; 42% of probands were female and 16% were non-European (**Table S1**). A median of 6 HPO terms (range=1-36) were recorded per proband, including 65% with global developmental delay/intellectual disability, and 72% of probands were the only affected member of their family.

#### GENETIC FINDINGS

To date, 19,285 potentially pathogenic sequence and structural variants have been identified in DDD probands and returned to referring clinicians through up to six rounds of iterative re-analysis and batch reporting, involving 18 different variant detection algorithms (**Figure 1**



and **Table S2**).<sup>7,15</sup> The majority of variants were identified using a clinically-curated database of 1,840 DD-associated genes (DDG2P)<sup>17</sup> which was updated at a rate of approximately 100 genes/year through literature curation and cohort-wide enrichment analyses (including 60 novel DD-associated genes identified by DDD; **Figure 2**);<sup>5,13,14,29,30</sup> 44% of reported variants were in genes added to DDG2P after the first round of reporting in 2014. The majority of reported variants were single nucleotide variants and small insertions/deletions detected using ES data (71% protein-altering, 19% protein-truncating, 3% non-coding variants), while structural variants were identified through a combination of microarray and ES analyses (6% copy number variants, 1% other structural variants; **Figure 2**). On average, one variant was reported per trio versus 2.5 per singleton proband (**Figure S1**), and probands with non-European ancestry had more variants reported (**Figure S2**). Each new round of analysis resulted in approximately one additional variant being reported for every six trios (**Figure S3**). Consistent with similar studies,<sup>31</sup> *de novo* variants in the proband and variants inherited from a mosaic parent (i.e. post-zygotic parental *de novo* variants) in dominant genes provided the highest diagnostic yield, with 79% of reported variants clinically classified as pathogenic/likely pathogenic; in contrast, 32% of variants in autosomal recessive conditions, 23% maternally inherited on the X-chromosome, 11% in autosomal dominant conditions inherited from an affected parent or with unknown inheritance were clinically classified as pathogenic/likely pathogenic (**Figure S4**).

There was a high rate of concordance between clinical and predicted classifications of variant pathogenicity and benignity (N=4425; sensitivity=99.5%, specificity=85.0%, PPV=96.5%, NPV=97.9%; **Figure S6**).<sup>25-27</sup> Discrepancies (N=149; 3%) were due to false positive variant calls, incorrect clinical classifications (e.g. atypical disease presentations) or inappropriate ACMG/ACGS criteria assignment (e.g. incorrect disease mechanisms). Based on concordance between clinical and predicted classifications of variant pathogenicity, we estimate that a minimum of 25% of probands (N=3347) are diagnosed, which rises to 32% (N=4363) for predicted only, 33% (N=4484) for clinical only, and 41% (N=5502) for either

clinical or predicted (**Figure 3**). Of those who were diagnosed by clinical assertion: 76% of those in family trios (N=2750/3599) have a pathogenic *de novo* variant (**Supplementary Information**); 13% (N=561) are partially diagnosed, and a further 3% (N=121) have two or more different genetic diagnoses potentially resulting in a composite phenotype, which rises to 7% (N=359) including computational predictions.<sup>32</sup> Although 30% (N=4021) have no reported variants, the rest of the cohort have either likely benign variants or variants of uncertain significance, of which 0.7% (N=99) have a predicted Bayesian posterior probability of pathogenicity 0.8-0.9. High rates of concordance were also seen in the subset of variants for which we were able to derive a phenotype-based gene-disease model using IMPROVE-DD,<sup>28</sup> and a further 18 variants of uncertain significance were raised to likely pathogenic based on the individual's phenotype.

#### FACTORS INFLUENCING DIAGNOSTIC RATE

We performed multiple logistic regression to investigate how demographic, clinical, phenotypic, prenatal and ancestral factors affected the chance of receiving a clinical diagnosis from the DDD study (**Figure 4**). The model explained ~14% of the variance. Being recruited in a parent-offspring trio had the largest impact on the chance of being diagnosed (OR: 4.70, 95% CI: 4.16-5.31). Other factors significantly increasing the chance of diagnosis included: having severe intellectual/ developmental delay (OR: 2.41, 95% CI: 2.10-2.76); time since recruitment (increased odds of diagnosis: 1.25 per additional year, 95% CI: 1.20-1.30); being the only affected family member (OR: 1.74, 95% CI: 1.57-1.92) or having fewer affected first-degree relatives (**Figure S7**); having features suggestive of a syndrome (OR: 1.23, 95% CI: 1.12-1.34); and having more organ systems affected (increased odds of diagnosis: 1.08 per additional organ system, 95% CI: 1.06-1.11). Probands born prematurely (OR: 0.73, 95% CI: 0.64-0.82), or who had *in utero* exposure to antiepileptic medications (OR: 0.44, 95% CI: 0.29-0.67) or whose mothers had diabetes (OR: 0.52, 95% CI: 0.41-0.67) were less likely to have a genetic diagnosis. Male sex (OR: 0.72, 95% CI: 0.67-0.79) also reduced the odds of getting a diagnosis, as did increasing homozygosity due to

consanguinity (decreased odds of diagnosis: 0.72 for each increase equivalent to the offspring of first cousins, 95% CI: 0.62-0.83). Probands with African ancestry had a lower diagnostic rate than those with other ancestries (OR: 0.51, 95% CI: 0.31-0.78), which was driven by fewer diagnoses in singleton probands (**Figure S8**).

## DISCUSSION

The DDD study has identified and communicated molecular diagnoses to thousands of families across the UK and Ireland affected by severe, previously undiagnosed developmental disorders. Despite excellent provision of clinical genetics and genetic testing services across the UK, these probands show how a genome-driven approach combined with detailed phenotyping can improve diagnostic yield over the previous standard of care. Our analysis highlights the value of using diverse and agnostic variant detection methodologies, combined with stringent variant filtering rules and repeated, iterative variant analysis and classification to enable new diagnoses to be made from existing data.<sup>15</sup>

The high burden of pathogenic *de novo* variants and current diagnostic yield of around 41% is consistent with similar studies.<sup>33</sup> Our analysis supports clinical intuition about the likelihood of establishing a molecular diagnosis in developmental disorders (e.g. availability of parental genotype data, as well as sex, ethnicity and phenotypic severity) and moves towards quantifying the expectation of making such a diagnosis. The work also highlights groups with lower diagnostic rates in our cohort (e.g. non-trios, families with multiple affected members, and those with non-European ancestry or high consanguinity), and reinforces the imperative to increase research participation for under-represented groups. Probands of African ancestry had a particularly low diagnostic rate, partly caused by the lack of ancestry-matched controls to estimate allele frequency and partly by being less likely to be recruited as a trio. Excluding cohort-specific factors, our multivariable logistic regression model predicts that probands in the top decile of probability of being diagnosed have a diagnostic

rate of 52% versus 16% in the bottom decile. We hypothesise that the lower diagnostic rate found in probands with certain prenatal risk factors reflects a larger role for environmental influences in these individuals. Prematurity<sup>34</sup>, maternal diabetes<sup>35</sup> and *in utero* exposure to antiepileptic medications<sup>36</sup> are known risk factors for developmental disorders. Further exploration is needed to better understand the relative contributions and interplay of genetic/environmental influences in this cohort.

The genetic architecture of developmental disorders is heterogeneous; although the large burden of highly-penetrant *de novo* variants facilitates both diagnosis and large-scale gene-disease discovery,<sup>5</sup> the number of composite and partial diagnoses suggests that many individuals are likely to have multiple contributing factors, including rare and common incompletely penetrant genetic variants and non-genetic causes. Under a liability threshold model of disease,<sup>37</sup> probands who have a substantial environmental contribution may require less severe or even no large-effect genetic variants to develop a neurodevelopmental disorder. Nonetheless, statistical burden analyses suggest that many more diagnoses remain in protein-coding genes than in non-coding elements,<sup>38</sup> which will likely be identified through novel DD-associated gene discovery (especially for dominant disorders), evaluation of incompletely penetrant variants, and functional assays to improve interpretation of existing candidate variants. Ultimately, clinical interpretation remains indispensable for determining the relevance of genomic findings for an individual patient.

The DDD study pioneered a hybrid clinical-research approach, requiring development of new methodologies to facilitate both large-scale analysis and individual variant feedback, which has since become standard practice in genomic medicine. The study primarily recruited infants and children and hence pioneered a conservative approach to individual variant feedback that focussed on diagnosis,<sup>7-9</sup> whilst exploring attitudes to communicating incidental findings<sup>39</sup> that influenced subsequent approaches.<sup>1</sup> A large network of expert clinician-researchers and the integration of ethics at a high level throughout the project

lifecycle served to both facilitate collaboration and enable real-time ethical issues to be openly and responsibly addressed (**Table 1**). To date, in addition to making thousands of new diagnoses for patients, the DDD study has resulted in >270 publications (<https://www.ddduk.org/publications.html>), identified around 60 new disorders and enabled >350 genotype/phenotype-specific projects led by clinician-researchers across all 24 recruitment sites. DECIPHER<sup>12</sup> was another key component of the DDD study, enabling nationwide recruitment, systematic phenotyping, individual feedback, variant interpretation and data sharing. DECIPHER is a live online platform enabling reported variants to be re-evaluated with current data (e.g. gene-disease associations, population frequencies, co-located variants reported in ClinVar, DECIPHER or publications) each time a patient is reviewed in the clinic, thus facilitating new opportunities for diagnosis as knowledge grows.

Although many of our conclusions are widely applicable across a range of rare diseases, the generalisability is limited by a number of factors. Recruitment of families following clinician-led differential diagnosis and routine diagnostic testing (karyotyping, aCGH and targeted single gene testing) resulted in a cohort likely depleted of clinically recognisable syndromes, large pedigrees with segregating pathogenic variants, recessive conditions in consanguineous families, and large structural variants. These biases will reduce the estimated diagnostic yield relative to first-tier testing, and skew the factors affecting getting a diagnosis. The diagnostic yield in DDD therefore represents a conservative estimate with higher yields anticipated if genomic sequencing had been offered as a first-line investigation. Our genotyping approach (ES and microarrays) did not assay most non-coding variants and could not detect all complex structural variants or tissue-specific mosaicism, and our analytical approach was insensitive to incomplete penetrance. Furthermore, the study was not funded to capture longitudinal phenotype data, evaluate parental phenotypes in detail, record the impact of diagnosis on subsequent clinical management of families, or comprehensively assess social or environmental contributions to developmental disorders –

all of which, in retrospect, would have enhanced the project. Finally, despite the large cohort size, due to the enormous genetic and phenotypic heterogeneity, we often had insufficient probands (particularly across different ancestries) with the same ultra-rare condition to enable confident variant interpretation, highlighting the need to aggregate phenotype information and structured electronic health data across cohorts internationally to improve variant interpretation.

That being said, through its pioneering genomic analysis of a large clinical cohort using a hybrid clinical-research model, the DDD study shows how the fusion of clinical expertise, genomic science and bioinformatics can drive diagnosis and discovery in families for whom standard clinically-driven diagnostic approaches have failed.

## **ACKNOWLEDGEMENTS**

The authors are deeply indebted to the patients and families involved in the DDD study, as well as the UK NHS and Irish HSE genetics services and the many scientists who have worked on DDD data at the Wellcome Sanger Institute (**Supplementary Information**). The study has UK Research Ethics Committee approval (10/H0305/83, granted by the Cambridge South REC, and GEN/284/12 granted by the Republic of Ireland REC). The research team acknowledges the support of the National Institute for Health Research, through the Comprehensive Clinical Research Network. The study uses DECIPHER (<https://www.deciphergenomics.org>), which is funded by Wellcome [grant number WT206194]. PC was supported by an NIHR Academic Clinical Fellowship.

## **Funding**

The DDD study presents independent research commissioned by the Health Innovation Challenge Fund [grant number HICF-1009-003], a parallel funding partnership between the Wellcome Trust and the Department of Health, and the Wellcome Sanger Institute [grant

number WT098051]. DECIPHER is funded by Wellcome [WT223718/Z/21/Z]. The views expressed in this publication are those of the author(s) and not necessarily those of the Wellcome Trust or the Department of Health.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

## REFERENCES

1. 100,000 Genomes Project Pilot Investigators, Smedley D, Smith KR, et al. 100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care - Preliminary Report. *N Engl J Med* 2021;385(20):1868–80.
2. Adams DR, Eng CM. Next-Generation Sequencing to Diagnose Suspected Genetic Disorders. *N Engl J Med* 2018;379(14):1353–62.
3. Lalonde E, Rentas S, Lin F, Dulik MC, Skraban CM, Spinner NB. Genomic diagnosis for pediatric disorders: revolution and evolution. *Front Pediatr* 2020;8:373.
4. Bennett CA, Petrovski S, Oliver KL, Berkovic SF. ExACTly zero or once: A clinically helpful guide to assessing genetic variants in mild epilepsies. *Neurol Genet* 2017;3(4):e163.
5. Kaplanis J, Samocha KE, Wiel L, et al. Evidence for 28 genetic disorders discovered by combining healthcare and research data. *Nature* 2020;586(7831):757–62.
6. Beaulieu CL, Majewski J, Schwartzentruber J, et al. FORGE Canada Consortium: outcomes of a 2-year national rare-disease gene-discovery project. *Am J Hum Genet* 2014;94(6):809–17.
7. Wright CF, Fitzgerald TW, Jones WD, et al. Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data. *Lancet* 2015;385(9975):1305–14.
8. Wright CF, Hurles ME, Firth HV. Principle of proportionality in genomic data sharing. *Nat Rev Genet* 2016;17(1):1–2.
9. Wright CF, Middleton A, Barrett JC, et al. Returning genome sequences to research participants: Policy and practice. [version 1; peer review: 2 approved]. *Wellcome Open Res* 2017;2:15.
10. Middleton A, Parker M, Wright CF, Bragin E, Hurles ME, DDD Study. Empirical research on the ethics of genomic research. *Am J Med Genet A* 2013;161A(8):2099–101.
11. Köhler S, Doelken SC, Mungall CJ, et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. *Nucleic Acids Res* 2014;42(Database issue):D966-74.
12. Firth HV, Richards SM, Bevan AP, et al. DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. *Am J Hum Genet* 2009;84(4):524–33.
13. Deciphering Developmental Disorders Study. Large-scale discovery of novel genetic causes of developmental disorders. *Nature* 2015;519(7542):223–8.
14. Deciphering Developmental Disorders Study. Prevalence and architecture of de novo mutations in developmental disorders. *Nature* 2017;542(7642):433–8.
15. Wright CF, McRae JF, Clayton S, et al. Making new genetic diagnoses with old data: iterative reanalysis and reporting from genome-wide data in 1,133 families with



- developmental disorders. *Genet Med* 2018;20(10):1216–23.
16. Ramu A, Noordam MJ, Schwartz RS, et al. DeNovoGear: de novo indel and point mutation discovery and phasing. *Nat Methods* 2013;10(10):985–7.
  17. Thormann A, Halachev M, McLaren W, et al. Flexible and scalable diagnostic filtering of genomic variants using G2P with Ensembl VEP. *Nat Commun* 2019;10(1):2373.
  18. Wright CF, Eberhardt RY, Constantinou P, Hurles ME, FitzPatrick DR, Firth HV. Evaluating variants classified as pathogenic in ClinVar in the DDD Study. *Genet Med* 2020;
  19. Wright CF, Prigmore E, Rajan D, et al. Clinically-relevant postzygotic mosaicism in parents and children with developmental disorders in trio exome sequencing data. *Nat Commun* 2019;10(1):2985.
  20. Wright CF, Quaife NM, Ramos-Hernández L, et al. Non-coding region variants upstream of MEF2C cause severe developmental disorder through three distinct loss-of-function mechanisms. *Am J Hum Genet* 2021;108(6):1083–94.
  21. Lord J, Gallone G, Short PJ, et al. Pathogenicity and selective constraint on variation near splice sites. *Genome Res* 2019;29(2):159–70.
  22. Gardner EJ, Sifrim A, Lindsay SJ, et al. Detecting cryptic clinically relevant structural variation in exome-sequencing data increases diagnostic yield for developmental disorders. *Am J Hum Genet* 2021;108(11):2186–94.
  23. Gardner EJ, Prigmore E, Gallone G, et al. Contribution of retrotransposition to developmental disorders. *Nat Commun* 2019;10(1):4630.
  24. Eberhardt RY, Wright CF, FitzPatrick DR, Hurles ME, Firth HV. Detection of mosaic chromosomal alterations in children with severe developmental disorders recruited to the DDD study. *medRxiv* 2022;
  25. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015;17(5):405–24.
  26. Ellard S, Baple E, Callaway A, Berry I, Forrester N, Clare. ACGS Best Practice Guidelines for Variant Classification in Rare Disease 2020. 2020;
  27. Tavgigian SV, Greenblatt MS, Harrison SM, et al. Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework. *Genet Med* 2018;20(9):1054–60.
  28. Aitken S, Firth HV, Wright CF, Hurles ME, FitzPatrick DR, Semple CA. IMPROVE-DD: Integrating Multiple Phenotype Resources Optimises Variant Evaluation in genetically determined Developmental Disorders. *HGG Adv* 2023; 4(1):100162.
  29. Martin HC, Jones WD, McIntyre R, et al. Quantifying the contribution of recessive coding variation to developmental disorders. *Science* 2018;362(6419):1161–4.
  30. Akawi N, McRae J, Ansari M, et al. Discovery of four recessive developmental disorders using probabilistic genotype and phenotype matching among 4,125 families. *Nat Genet* 2015;47(11):1363–9.
  31. Vissers LELM, de Ligt J, Gilissen C, et al. A de novo paradigm for mental retardation.

- Nat Genet 2010;42(12):1109–12.
32. Posey JE, Harel T, Liu P, et al. Resolution of Disease Phenotypes Resulting from Multilocus Genomic Variation. *N Engl J Med* 2017;376(1):21–31.
  33. Srivastava S, Love-Nichols JA, Dies KA, et al. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. *Genet Med* 2019;21(11):2413–21.
  34. Blencowe H, Lee ACC, Cousens S, et al. Preterm birth-associated neurodevelopmental impairment estimates at regional and global levels for 2010. *Pediatr Res* 2013;74 Suppl 1:17–34.
  35. Chen S, Zhao S, Dalman C, Karlsson H, Gardner R. Association of maternal diabetes with neurodevelopmental disorders: autism spectrum disorders, attention-deficit/hyperactivity disorder and intellectual disability. *Int J Epidemiol* 2021;50(2):459–74.
  36. Coste J, Blotiere P-O, Miranda S, et al. Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France. *Sci Rep* 2020;10(1):17362.
  37. Walsh R, Tadros R, Bezzina CR. When genetic burden reaches threshold. *Eur Heart J* 2020;41(39):3849–55.
  38. Short PJ, McRae JF, Gallone G, et al. De novo mutations in regulatory elements in neurodevelopmental disorders. *Nature* 2018;555(7698):611–6.
  39. Middleton A, Morley KI, Bragin E, et al. Attitudes of nearly 7000 health professionals, genomic researchers and publics toward the return of incidental results from sequencing research. *Eur J Hum Genet* 2016;24(1):21–9.
  40. Choufani S, Cytrynbaum C, Chung BHY, et al. NSD1 mutations generate a genome-wide DNA methylation signature. *Nat Commun* 2015;6:10207.

## FIGURES

### Figure 1. Overview of DDD variant detection and filtering pipelines.

Physician-patient interactions within the DDD study were supported by the DECIPHER database, including recruitment, barcoded sample collection and phenotyping at the start, and variant reporting, diagnostic interpretation and discussion of results at the end. Genomic assays are shown in grey boxes, variants in blue boxes, variant subsets in light blue circles, and reported and diagnostic variants in red boxes; variant callers and analytical processes are annotated on arrows (further detail and references in **Supplementary Information**). Once candidate variants were deposited into DECIPHER, clinical judgement was used to assess whether a patient's phenotype fitted with the genotype prior to returning confirmed diagnoses to families. Diagrams were taken from [www.ddduk.org](http://www.ddduk.org).

*aCGH* = array comparative genomic hybridisation; *CNVs* = copy number variants; *DDG2P* = Developmental Disorders Gene2Phenotype database; *indels* = insertions/deletions; *MAF* = minor allele frequency; *MEI* = mobile element insertion; *OMIM* = Online Mendelian Inheritance in Man database; *P/LP* = pathogenic/likely pathogenic (variants in the ClinVar database); *SNP* = single nucleotide polymorphism; *SNVs* = single nucleotide variants; *SVs* = structural variants; *UPD* = uniparental disomy; *uORFs* = upstream open reading frames; *VEP* = Variant Effect Predictor; *VCFs* = variant call files.

### Figure 2. Summary of DDD variant deposition into DECIPHER..

(a) Variant classes reported into DECIPHER. Sequence variants were detected using ES and included variants <100bp in DDG2P genes; structural variants range from >100bp to whole chromosomes and were detected using microarrays and ES. (b) Changes in DDG2P and number of variants reported and annotated as pathogenic/likely pathogenic with time. Gene-disease entities were added to the DDG2P database following curation of the literature by consultant clinical geneticists or burden analyses within the DDD study. Participants were sequenced and analysed in batches based on recruitment date, sample receipt and family

trio status. Variant filtering was repeated over the course of the study to enable evaluation of novel variants and variants in newly included genes. As a result of this iterative variant filtering strategy, some probands were evaluated up to six times and all were evaluated at least twice (see **Figure S3**). Following evaluation, variants were deposited into DECIPHER, usually in batches, for evaluation by clinical teams. Clinical annotation of pathogenicity was not immediate up deposition, but once annotated, the vast majority (97%) of variants did not change their annotation. Blue bars = cumulative number of reportable DDG2P genes; red dotted line = cumulative number of total DDD variants deposited into DECIPHER; red continuous line = cumulative number of clinically annotated pathogenic/likely pathogenic DDD variants in DECIPHER.

### **Figure 3. Summary of diagnoses in the DDD study.**

**(a)** Venn diagram showing overlap of diagnoses based on clinical assertion (white) versus predicted ACMG/ACGS variant classifications (grey), augmented with phenotype-based IMPROVE-DD gene-disease models (blue); figure created using eulerr. **(b)** Diagnostic ranges in trios and singleton probands, based on clinical and/or predicted variant classifications. **(c)** Example of computational Bayesian variant classification, incorporating genotypic and phenotypic data in a DDD proband: only PM2 could be applied to the missense variant, resulting in an uncertain classification, but the proband's phenotype was consistent with the IMPROVE-DD model for *NSD1*, allowing the variant to be upgraded to likely pathogenic; additional data (e.g. epigenomic profiling)<sup>40</sup> was used to further increase the robustness of the diagnosis of Sotos syndrome.

### **Figure 4. Factors influencing the probability of being diagnosed.**

Odds associated with being fully or partially diagnosed by the DDD study (based on clinician assertions of variant pathogenicity) are shown for covariates included in a multivariable logistic regression, adjusted for recruitment centre and number of variants reported in DECIPHER. Odds ratios are presented for binary and categorical variables. For quantitative

variables (*italics*), odds change per one unit of measure of increase are presented. P-values and 95% confidence intervals are also shown; underline in variable column = outcome variable plotted, with N referring to the number of probands in this group. See **Supplementary Information** for further analysis of the number of affected first-degree relatives (**Figure S6**) and ancestry (**Figure S7 and S8**)

## TABLES

**Table 1. Ethical considerations in the DDD study.**

The DDD study depended crucially upon integration of ethics into decision-making and collaboration-building, both upfront and throughout the project, allowing important ethical questions to be identified and ethical policies to be developed through a consensual process.

Ethical Domain	Key Issues	Resolution within DDD Study
<b>Building and maintaining partnerships at clinical-research interface</b>	<ul style="list-style-type: none"> <li>● Ensuring trust between researchers, clinicians, and patients/families.</li> <li>● Trade-off between creating large research dataset versus maintaining small clinical cohorts.</li> <li>● Managing practical ethical considerations throughout the lifecycle of the DDD study.</li> </ul>	<ul style="list-style-type: none"> <li>● Scientific scope limited to understanding causes of developmental disorders.</li> <li>● Local training sessions and regular discussion with stakeholders around project planning and decisions.</li> <li>● Regular DDD management committee meetings and annual national collaborators meetings.</li> </ul>
<b>Recruitment, consent, capacity, and eligibility</b>	<ul style="list-style-type: none"> <li>● Most DDD probands lack capacity to give consent, either due to young age or intellectual disability.</li> <li>● Challenging to recruit under-represented ethnic minorities into research studies.</li> <li>● Initial DDD eligibility limited to those &lt;16 years, creating inequity; however, recruitment of adults lacking capacity is extremely challenging in Scotland.</li> <li>● Confidentiality of DDD study participants should be protected where possible.</li> </ul>	<ul style="list-style-type: none"> <li>● Detailed consent materials and website developed for families/guardians.</li> <li>● DDD consent materials translated into several different languages.</li> <li>● New consent materials written, and recruitment opened to adults with/without capacity in England, Wales, Northern Ireland, and Ireland.</li> <li>● Pseudonymised IDs used throughout study; minimum data required for research stored and personal identifiable data (such as date of birth) not stored within DECIPHER.</li> </ul>
<b>Sample inclusion, collection, and verification</b>	<ul style="list-style-type: none"> <li>● Balance between scientific benefit of sampling parents and clinical concerns around scope and data management.</li> <li>● Many children with developmental disorders are very distressed by hospital visits to have blood samples drawn.</li> <li>● Sample mix-ups in DDD (either within families, at recruitment centres or at the Wellcome Sanger Institute).</li> </ul>	<ul style="list-style-type: none"> <li>● Parents recruited into DDD with the agreement that their data would only be used where it is relevant to understanding their child's disorder.</li> <li>● Saliva sample kits used to collect child and parental samples, allowing sample collection at home.</li> <li>● Genetic 'barcodes' for all samples created using 60 SNP-genotyping; individual and family data cross-checked</li> <li>● Potential safeguarding issues flagged with referring clinical team; discordant</li> </ul>

	<ul style="list-style-type: none"> <li>● Potential for detection of incest or misattributed parentage</li> </ul>	<p>samples or biologically unrelated parents excluded from further analysis.</p>
<p><b>Sharing clinically-relevant variants</b></p>	<ul style="list-style-type: none"> <li>● Public opinion about feedback of incidental findings from genomics research largely unknown and unexplored.</li> <li>● Balance between benefits and harms of returning different types of clinically actionable findings.</li> <li>● Pertinent findings (i.e. potentially relevant to the child's developmental disorder) deemed within the scope of research study and clinical testing, where benefits likely to outweigh harms.</li> <li>● Incidental findings deemed outside the scope and expertise of clinicians/researchers, with unclear relevance particularly in children, where harms likely to outweigh benefits.</li> </ul>	<ul style="list-style-type: none"> <li>● Ethics/social science researcher embedded in DDD study to investigate attitudes amongst the public, patients, scientists and health professionals to feedback of incidental findings in genomics.</li> <li>● DDD documentation states that pertinent findings would be reported to clinical teams for communication with families, but not incidental findings.</li> <li>● DDG2P database and variant filtering rules developed to select plausibly pathogenic variants for reporting into linked DECIPHER records; DDG2P genes associated with adult-onset diseases flagged for review.</li> <li>● Pathogenic variants and phenotypes shared openly via DECIPHER once family had been informed.</li> </ul>
<p><b>Sharing genome-wide variants</b></p>	<ul style="list-style-type: none"> <li>● Requests received from DDD parents for genomic data to be returned directly to them.</li> <li>● Access to research data should be prioritised for the hundreds of clinicians and scientists involved in recruitment and management of DDD families.</li> <li>● Research data should be shared widely with external researchers to advance research, but datasets are sensitive as they relate to severely unwell children and consent is limited to understanding causes of DD.</li> </ul>	<ul style="list-style-type: none"> <li>● Requests for individual/family genomic data declined based on concerns about sample identity, lack of resources to provide informatics support, and inability to mitigate against unintended consequences.</li> <li>● Collaborative Analysis Project system created, with research plans reviewed by management committee and data shared by secure file transfer protocol.</li> <li>● Genomic data shared with <i>bona fide</i> researchers under managed access via EGA; anonymised variants of potential relevance shared through DECIPHER as research variants.</li> </ul>

<p><b>Managing withdrawal</b></p>	<ul style="list-style-type: none"> <li>● DDD participants are allowed to withdraw from the study at any time, requiring a range of actions to manage samples, data, and associated records.</li> <li>● Previously shared data cannot be withdrawn and may be required to support published findings.</li> </ul>	<ul style="list-style-type: none"> <li>● Upon receiving a withdrawal request, samples are destroyed, unshared data are removed, and individual DECIPHER records are deleted to break any link to the family.</li> <li>● Data in previously published datasets not withdrawn, as stated in consent materials.</li> </ul>
-----------------------------------	---	---